Ultragenyx Pharmaceutical (RARE) has an average broker rating of 1.23, which is interpreted as a Strong Buy, as rated by 13 equity analysts. Nonetheless, 11 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Ultragenyx Pharmaceutical (RARE) : The highest level Ultragenyx Pharmaceutical (RARE) is projected to reach is $125 for the short term and the lowest estimate is at $70. The consolidated price target from 12 rating analysts who initiate coverage on the stock is $92.58 and the possibility the share price can swing is $15.27.
Shares of Ultragenyx Pharmaceutical Inc. rose by 5.64% in the last five trading days and 27.92% for the last 4 weeks. Ultragenyx Pharmaceutical Inc. is up 1.58% in the last 3-month period. Year-to-Date the stock performance stands at -38.17%. Ultragenyx Pharmaceutical (NASDAQ:RARE): stock turned positive on Tuesday. Though the stock opened at $68.53, the bulls momentum made the stock top out at $70.6 level for the day. The stock recorded a low of $67.94 and closed the trading day at $69.36, in the green by 1.85%. The total traded volume for the day was 856,126. The stock had closed at $68.1 in the previous days trading.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).